Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-throughput detection of clinically targetable alterations using next-generation sequencing.

Julie A Vendrell1, David Grand2, Isabelle Rouquette2

  • 1CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, France.

Oncotarget
|April 14, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bullous immunoglobulin A dermatosis following oral contrast in a patient with dermatitis herpetiformis.

JAAD case reports·2026
Same author

Do not underestimate cryptosporidium: case report of a rare cause of acute liver failure in transplant recipients.

BMC infectious diseases·2026
Same author

Integrated DNA and RNA profiling refines prognostic stratification independent of therapeutic actionability in cholangiocarcinoma.

BMC cancer·2026
Same author

Cutaneous <i>Mycobacterium llatzerense</i> in an immunocompetent woman: Case report and literature review.

JAAD case reports·2026
Same author

From clusters to clinic: An 8-gene signature combined with mucinous component stratifies benefit of anti-CTLA-4 addition to anti-PD-1 in dMMR/MSI-H metastatic colorectal cancer.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Molecular endoscopy with next-generation sequencing improves diagnosis of cholangiocarcinoma in patients with extrahepatic biliary strictures.

JHEP reports : innovation in hepatology·2026
This summary is machine-generated.

This study introduces a new next-generation sequencing (NGS) panel for detecting actionable cancer mutations, even in challenging formalin-fixed, paraffin-embedded (FFPE) samples. The assay improves molecular diagnosis rates and identifies novel therapeutic targets for cancer patients.

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Next-generation sequencing (NGS) offers high-throughput gene analysis for cancer care.
  • Current commercial cancer panels often include non-actionable mutations and struggle with degraded formalin-fixed, paraffin-embedded (FFPE) samples.

Purpose of the Study:

  • To design and validate a novel amplicon-based NGS panel targeting 16 actionable genes for routine clinical use.
  • To assess the panel's performance on FFPE samples and its impact on molecular diagnosis rates.

Main Methods:

  • Development of a targeted NGS panel with short amplicons (<150 bp) and dual-strand library preparation.
  • Clinical validation using well-characterized controls and 140 FFPE tumor samples with degraded DNA.
  • Assessment of reproducibility and detection limits for actionable alterations.
Keywords:
NGS cancer panelmolecular diagnosisroutine practicetargeted therapies

Related Experiment Videos

Main Results:

  • High inter-laboratory and inter-run reproducibility achieved.
  • Detection of clinically actionable alterations in FFPE samples with variant allele frequencies as low as 1%.
  • Increased molecular diagnosis rate from 40.7% to 59.2%, identifying 41 novel actionable alterations.

Conclusions:

  • The developed NGS panel is a robust, scalable, and clinically relevant tool for actionable mutation detection in FFPE samples.
  • The panel enhances molecular diagnosis and facilitates the identification of new therapeutic targets in daily hospital and academic laboratory practice.